2013 Q1 Form 10-Q Financial Statement
#000110465913040291 Filed on May 10, 2013
Income Statement
| Concept | 2013 Q1 | 2012 Q4 | 2012 Q1 |
|---|---|---|---|
| Revenue | $5.562M | $1.968M | $114.0K |
| YoY Change | 4778.95% | 1620.31% | 100.0% |
| Cost Of Revenue | $2.408M | ||
| YoY Change | |||
| Gross Profit | $3.154M | ||
| YoY Change | |||
| Gross Profit Margin | 56.71% | ||
| Selling, General & Admin | $2.310M | $4.190M | $1.830M |
| YoY Change | 26.23% | 143.6% | 15.09% |
| % of Gross Profit | 73.24% | ||
| Research & Development | $300.0K | $2.515M | $5.183M |
| YoY Change | -94.21% | -62.48% | -65.13% |
| % of Gross Profit | 9.51% | ||
| Depreciation & Amortization | $145.0K | $480.0K | $30.87K |
| YoY Change | 369.77% | 1500.0% | -26.41% |
| % of Gross Profit | 4.6% | ||
| Operating Expenses | $2.750M | $2.515M | $5.183M |
| YoY Change | -46.94% | -62.48% | -65.13% |
| Operating Profit | $403.0K | -$3.635M | -$6.932M |
| YoY Change | -105.81% | -56.42% | -57.84% |
| Interest Expense | $93.00K | $124.2K | |
| YoY Change | -25.12% | -27.79% | |
| % of Operating Profit | 23.08% | ||
| Other Income/Expense, Net | -$50.00K | ||
| YoY Change | |||
| Pretax Income | $260.0K | $22.24M | -$10.26M |
| YoY Change | -102.53% | -434.44% | -40.52% |
| Income Tax | $0.00 | $90.00K | $0.00 |
| % Of Pretax Income | 0.0% | 0.4% | |
| Net Earnings | $260.0K | $22.22M | -$10.26M |
| YoY Change | -102.53% | -434.14% | -40.52% |
| Net Earnings / Revenue | 4.67% | 1129.31% | -9000.0% |
| Basic Earnings Per Share | $0.00 | ||
| Diluted Earnings Per Share | $0.00 | -$3.176M | |
| COMMON SHARES | |||
| Basic Shares Outstanding | 0.000 shares | ||
| Diluted Shares Outstanding | 0.000 shares |
Balance Sheet
| Concept | 2013 Q1 | 2012 Q4 | 2012 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $29.40M | $0.00 | $49.50M |
| YoY Change | -40.61% | -100.0% | -3.51% |
| Cash & Equivalents | $41.00K | $11.00K | $49.47M |
| Short-Term Investments | |||
| Other Short-Term Assets | $2.600M | $300.0K | $700.0K |
| YoY Change | 271.43% | -62.5% | -36.36% |
| Inventory | $2.810M | ||
| Prepaid Expenses | $313.0K | ||
| Receivables | $5.432M | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $31.93M | $8.566M | $50.20M |
| YoY Change | -36.4% | -85.24% | -4.38% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $0.00 | $4.880M | $900.0K |
| YoY Change | -100.0% | 466.54% | 12.5% |
| Goodwill | $0.00 | ||
| YoY Change | |||
| Intangibles | $85.00K | ||
| YoY Change | |||
| Long-Term Investments | $3.400M | $3.400M | |
| YoY Change | 0.0% | 0.0% | |
| Other Assets | $0.00 | $302.3K | $100.0K |
| YoY Change | -100.0% | 202.29% | 0.0% |
| Total Long-Term Assets | $3.430M | $5.182M | $4.400M |
| YoY Change | -22.05% | 19.03% | 2.33% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $31.93M | $8.566M | $50.20M |
| Total Long-Term Assets | $3.430M | $5.182M | $4.400M |
| Total Assets | $35.36M | $13.75M | $54.60M |
| YoY Change | -35.24% | -77.96% | -3.87% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $200.0K | $1.994M | $3.300M |
| YoY Change | -93.94% | -36.71% | -61.18% |
| Accrued Expenses | $1.000M | $927.0K | $2.800M |
| YoY Change | -64.29% | -77.39% | -6.67% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $4.100M | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $8.200M | ||
| YoY Change | |||
| Total Short-Term Liabilities | $9.300M | $7.712M | $6.100M |
| YoY Change | 52.46% | 6.7% | -51.59% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $48.80M | $10.50M |
| YoY Change | -100.0% | 182.08% | -41.67% |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $48.80M | $10.50M |
| YoY Change | -100.0% | 182.08% | -41.67% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $9.300M | $7.712M | $6.100M |
| Total Long-Term Liabilities | $0.00 | $48.80M | $10.50M |
| Total Liabilities | $9.326M | $10.59M | $16.60M |
| YoY Change | -43.82% | -56.87% | -45.93% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$247.2M | -$43.80M | -$227.5M |
| YoY Change | 8.68% | -79.84% | |
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $0.00 | ||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $26.03M | -$42.72M | $38.00M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $35.40M | $13.75M | $54.57M |
| YoY Change | -35.14% | -77.96% | -3.92% |
Cashflow Statement
| Concept | 2013 Q1 | 2012 Q4 | 2012 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $260.0K | $22.22M | -$10.26M |
| YoY Change | -102.53% | -434.14% | -40.52% |
| Depreciation, Depletion And Amortization | $145.0K | $480.0K | $30.87K |
| YoY Change | 369.77% | 1500.0% | -26.41% |
| Cash From Operating Activities | -$230.0K | $21.98M | -$7.690M |
| YoY Change | -97.01% | -301.1% | -26.55% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $108.0K | $240.0K | $54.23K |
| YoY Change | 99.14% | -442.86% | -75.49% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $10.00K | -$10.00K |
| YoY Change | -100.0% | ||
| Cash From Investing Activities | -$110.0K | $250.0K | -$60.00K |
| YoY Change | 83.33% | -457.14% | -72.73% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $372.0K | -3.040M | 0.000 |
| YoY Change | 120.29% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -230.0K | 21.98M | -7.690M |
| Cash From Investing Activities | -110.0K | 250.0K | -60.00K |
| Cash From Financing Activities | $372.0K | -3.040M | 0.000 |
| Net Change In Cash | $372.0K | 19.19M | -7.750M |
| YoY Change | -104.8% | -255.01% | -158.71% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$230.0K | $21.98M | -$7.690M |
| Capital Expenditures | $108.0K | $240.0K | $54.23K |
| Free Cash Flow | -$338.0K | $21.74M | -$7.744M |
| YoY Change | -95.64% | -300.18% | -27.56% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
378803 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
35173144 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
166386 | USD |
| CY2012Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
3413762 | USD |
| CY2012Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
15878 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
38769170 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1128644 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1078683 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
502452 | USD |
| CY2012Q4 | us-gaap |
Senior Notes Current
SeniorNotesCurrent
|
7883886 | USD |
| CY2012Q4 | us-gaap |
Liabilities
Liabilities
|
10593665 | USD |
| CY2013Q1 | us-gaap |
Assets Current
AssetsCurrent
|
31926746 | USD |
| CY2013Q1 | us-gaap |
Assets
Assets
|
35356386 | USD |
| CY2013Q1 | us-gaap |
Liabilities
Liabilities
|
9325736 | USD |
| CY2013Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-247247536 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-244956887 | USD |
| CY2013Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
26030650 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38769170 | USD |
| CY2013Q1 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
273278186 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
273132392 | USD |
| CY2012Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5183217 | USD |
| CY2012Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
30866 | USD |
| CY2012Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
7045935 | USD |
| CY2012Q1 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-3210338 | USD |
| CY2012Q1 | us-gaap |
Interest Expense
InterestExpense
|
124196 | USD |
| CY2012Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1992 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10264477 | USD |
| CY2013Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
BIOSANTE PHARMACEUTICALS INC | |
| CY2013Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001023024 | |
| CY2013Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2013Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-03-31 | |
| CY2013Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2013Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2013Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
34794341 | USD |
| CY2013Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">                                     </font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">DESCRIPTION OF BUSINESS</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">BioSante Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.  The Company’s products, either approved or in human clinical development, include: (1) LibiGel, once daily transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2) a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA, Inc. (Teva); (3) The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (4) Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals, Inc. (Meda), the Company’s licensee.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">On October 3, 2012, the Company entered into an agreement and plan of merger (the Prior Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI).  The Prior Merger Agreement provided that, subject to the terms and conditions set forth in the Prior Merger Agreement, ANI would merge with and into the Company, with the Company continuing as the surviving company (the Prior Merger).  Following completion of the Prior Merger, stockholders of ANI immediately prior to the effective time of the Prior Merger were expected to own approximately 53% of the outstanding shares of common stock of the combined company, and stockholders of the Company immediately prior to the effective time of the Prior Merger were expected to own approximately 47% of the outstanding shares of common stock of the combined company, assuming the Company’s “net cash” as defined in the Prior Merger Agreement and generally consisting of the Company’s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Prior Merger, was $18.0 million.  The exchange ratios in the Prior Merger were subject to potential adjustment as described in the Prior Merger Agreement depending upon the amount of the Company’s net cash as of a determination date prior to the closing date of the Prior Merger, but in no event were ANI stockholders immediately prior to the effective time of the Prior Merger to own less than 50.1% (or Company stockholders immediately prior to the effective time of the Prior Merger to own more than 49.9%) of the outstanding shares of common stock of the combined company.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Prior Merger Agreement was approved by ANI’s stockholders on March 15, 2013.  The Company adjourned its special meeting of stockholders called to approve the Prior Merger until April 12, 2013 to give the Company’s stockholders additional time to vote.  As of April 12, 2013, voting instructions to vote shares in favor of the Prior Merger had been received from holders of approximately 36% of the outstanding shares of the Company’s capital stock, which was short of the required majority needed to approve the Prior Merger. Of those shares as to which voting instructions had been given, approximately 84% were to be voted in favor of the Prior Merger. However, no voting instructions on the Prior Merger had been received from holders of a total of approximately 13.8 million shares, or approximately 57% of the outstanding shares of the Company’s capital stock.  Two other proposals submitted to the Company’s stockholders in connection with the Prior Merger, a reverse stock split and a name change, also received affirmative voting instructions from holders of a majority of the shares as to which voting instructions were received, but neither received affirmative voting instructions with respect to the required majority of the outstanding shares of the Company’s capital stock.  Subsequent to March 15, 2013, the Company determined that it likely would not receive sufficient additional voting instructions prior to April 12, 2013 (or on any later date) to either approve the Prior Merger and the two other related proposals or to indicate that the Company’s stockholders had rejected the Prior Merger or these other proposals.  Accordingly, the Board of Directors of the Company decided to begin discussions with ANI about a possible restructured merger.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center;" align="center"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">On April 12, 2013, the Company, ANI Merger Sub, Inc., a newly created, wholly owned subsidiary of the Company formed solely for purposes of effecting the merger (Merger Sub), and ANI entered into an amended and restated agreement and plan of merger (the New Merger Agreement), pursuant to which, upon the terms and subject to the conditions set forth in such agreement, Merger Sub will be merged with and into ANI, and after which ANI will be a wholly owned subsidiary of the Company (the New Merger).  The New Merger Agreement supersedes and replaces in its entirety the Prior Merger Agreement.  Following consummation of the transactions contemplated by the New Merger Agreement, the stockholders of ANI immediately prior to the effective time of the New Merger will own 57% of the outstanding shares of common stock of the Company and the stockholders of the Company immediately prior to the effective time of the New Merger will own 43% of the outstanding shares of common stock of the Company.  The required Company stockholder vote for the New Merger will be a majority of the shares of the Company’s common stock and class C special stock present and entitled to vote at the stockholders meeting at which the issuance of shares of the Company’s common stock in connection with the New Merger will be considered. The proposed New Merger with ANI is more fully described in Note 3, “Proposed New Merger with ANI.”</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">On January 31, 2013, the Company entered into an asset purchase agreement with Aduro BioTech, Inc., a clinical-stage immunotherapy company (Aduro), pursuant to which the Company sold all of its assets related to its GVAX cancer vaccine portfolio in exchange for a $1.0 million cash payment plus the potential for future royalty, milestone and sublicense payments. The agreement with Aduro is more fully described in Note 9, “Sale of GVAX Cancer Vaccine Assets.”</font></p> </div> | |
| CY2013Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">                                     </font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">BASIS OF PRESENTATION</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of March 31, 2013 and December 31, 2012, the results of operations for the three months ended March 31, 2013 and 2012, and the cash flows for the three months ended March 31, 2013 and 2012, in conformity with accounting principles generally accepted in the United States of America.  Operating results for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2013. The Company does not have items of other comprehensive income for either of the three month periods ended March 31, 2013 or 2012; and therefore, has not presented comprehensive income.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">These unaudited interim condensed financial statements should be read in conjunction with the financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">On June 1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class C special stock.  These unaudited interim condensed financial statements give retroactive effect to the reverse stock split.</font></p> </div> | |
| CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29388772 | USD |
| CY2013Q1 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-285329 | USD |
| CY2012Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-62189 | USD |
| CY2012Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-7751502 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-5405569 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1260100 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4145469 | USD |
| CY2012Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
10132534 | USD |
| CY2012Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49473732 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
57225234 | USD |
| CY2013Q1 | us-gaap |
Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
|
1000000 | USD |
| CY2013Q1 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | USD |
| CY2012Q2 | bpax |
Stockholders Equity Reverse Stock Split Conversion Ratio
StockholdersEquityReverseStockSplitConversionRatio
|
0.1667 | pure |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.53 | |
| CY2012Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19377768 | shares |
| CY2013Q1 | us-gaap |
Revenues
Revenues
|
145040 | USD |
| CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
3087549 | USD |
| CY2013Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2290649 | USD |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.09 | |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24487451 | shares |
| CY2012Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-432 | USD |
| CY2012Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
313027 | USD |
| CY2012Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-84227 | USD |
| CY2012Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1063726 | USD |
| CY2012Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-7689313 | USD |
| CY2012Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
54234 | USD |
| CY2012Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
7955 | USD |
